VALN Valneva SE IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1836564 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.0%
TTM net income YoY-840.6%
TTM EPS YoY-750.0%
Revenue 3-yr CAGR-21.5%
Net income 3-yr CAGR—
Margins
Gross margin38.7%
Operating margin-47.0%
Net margin-66.0%
FCF margin-32.8%
EBITDA margin—
Returns
ROE-80.2%
ROA-25.6%
ROIC (approx.)-34.5%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets73.4%
Debt / equity1.69x
Current ratio2.38x
Interest coverage-1.96x
Cash quality & payout
Operating cash flow / net income0.46x
Accruals ratio-13.9%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 174.66M | 169.58M | 153.71M | 361.30M | 348.09M |
| Cost of revenue | 107.14M | 98.54M | 100.88M | 324.44M | 187.92M |
| Gross profit | 67.52M | 71.04M | 52.84M | 36.86M | 160.17M |
| R&D expense | 85.30M | 74.14M | 59.89M | 104.92M | 173.28M |
| SG&A expense | 37.32M | 42.75M | 47.80M | 34.07M | 47.61M |
| Operating income | -82.06M | 13.33M | -82.09M | -113.44M | -61.39M |
| Interest expense | 41.90M | 23.98M | 23.32M | 19.05M | 16.96M |
| Pretax income | -114.12M | -11.49M | -98.63M | -144.81M | -69.98M |
| Income tax | 1.07M | 761,000 | 2.80M | -1.54M | 3.45M |
| Net income | -115.19M | -12.25M | -101.43M | -143.28M | -61.39M |
| EBITDA | -60.31M | 32.92M | -64.50M | -92.41M | -47.11M |
| EPS (basic) | -0.68 | -0.08 | -0.73 | -1.24 | -0.75 |
| EPS (diluted) | -0.68 | -0.08 | -0.73 | -1.24 | -0.75 |
| Weighted avg. shares (diluted) | 168.18M | 145.71M | 138.62M | 115.47M | 97.62M |
| Balance sheet | |||||
| Cash & equivalents | 109.65M | 168.27M | 126.08M | 286.53M | 346.69M |
| Receivables | 27.81M | 35.20M | 41.65M | 23.91M | 44.01M |
| Inventory | 50.23M | 53.66M | 44.47M | 35.10M | 124.10M |
| Current assets | 222.54M | 299.01M | 262.82M | 424.66M | 585.83M |
| PP&E, netmay include right-of-use assets (IFRS) | 119.47M | 138.88M | 136.20M | 112.44M | 125.55M |
| Intangibles | 22.35M | 25.26M | 25.57M | 28.71M | 32.70M |
| Total assets | 398.84M | 500.03M | 460.06M | 621.34M | 817.35M |
| Current liabilities | 93.33M | 114.58M | 158.86M | 277.39M | 368.98M |
| Short-term debt | 17.91M | 20.85M | 44.08M | 11.58M | 7.11M |
| Long-term debt | 161.26M | 166.52M | 132.77M | 87.23M | 50.73M |
| Total debt | 179.17M | 187.37M | 176.85M | 98.81M | 57.83M |
| Total liabilities | 292.67M | 318.78M | 331.81M | 401.55M | 646.77M |
| Shareholders' equity | 106.17M | 181.25M | 128.25M | 219.80M | 170.58M |
| Net debt | 69.52M | 19.10M | 50.77M | -187.72M | -288.85M |
| Shares outstanding | 173.42M | 162.40M | 138.79M | 138.24M | 105.11M |
| Cash flow statement | |||||
| Operating cash flow | -52.89M | -67.22M | -202.74M | -245.34M | 76.90M |
| Capital expenditure | 4.42M | 13.87M | 14.23M | 29.25M | 92.23M |
| Free cash flow | -57.31M | -81.08M | -216.97M | -274.59M | -15.33M |
| Investing cash flow | -1.71M | 76.92M | -20.59M | -29.05M | -93.12M |
| Financing cash flow | -621,000 | 30.68M | 63.08M | 215.12M | 154.50M |
| Depreciation & amortization | 21.75M | 19.59M | 17.58M | 21.04M | 14.28M |
| Stock-based compensation | 9.53M | 7.97M | 5.11M | -8.66M | 14.51M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.